The 2016 News Archive of Autifony Therapeutics: researching treatments for hearing disorders – tinnitus & age related hearing loss - & schizophrenia

2016 News Archive

Autifony Announces Results from Completed CLARITY-1, Phase IIa Trial of AUT00063 in Age-related Hearing Loss

London, UK – 09 August 2016 - Autifony Therapeutics Limited, which is pioneering the development of novel pharmaceutical treatments for hearing disorders and other serious disorders of the central nervous system, today released the results of its CLARITY-1 clinical trial of AUT00063 conducted in subjects with age-related hearing loss.

Read more


Autifony Therapeutics successfully completes Phase I study of AUT00206, a first-in-class Kv3 modulator for schizophrenia

London, UK -  01 August 2016 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders and other serious disorders of the central nervous system, today announced successful completion of a Phase I clinical evaluation of its Kv3 modulator, AUT00206. 

Read more


Autifony Therapeutics initiates QuicK+fire, a pilot study of AUT00063 in adult cochlear implant users

London, UK -  6th July 2016 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing loss, today announced the start of a pilot study (called QuicK+fire) to evaluate its lead compound, AUT00063, in adult cochlear implant (CI) users. The study, which will be conducted in the UK, is aimed at helping to improve the hearing of adult CI users, particularly in challenging environments such as with background noise. AUT0063 is currently being tested in a Phase IIa clinical trial in age related hearing loss in the United States. 

Read more


Update from Autifony Therapeutics’ QUIET-1 tinnitus clinical trial

  • Headline data from QUIET-1 confirm lack of efficacy of AUT00063 in the treatment of people with mild-to-moderate tinnitus
  • AUT00063 was safe and well tolerated
  • Trial of AUT00063 in age-related hearing loss continuing

London, UK – 28th April 2016- Autifony, along with Innovate UK, sponsored a Phase IIa tinnitus clinical trial in the UK. Professor Jaydip Ray, ENT Surgeon at Sheffield Teaching Hospitals & Sheffield Children's Hospital, was the national Coordinating Investigator for this clinical trial. Our lead academic collaborator was the University of Nottingham (Professor Deborah Hall). This "proof-of-concept" study explored the potential of Autifony's lead Kv3 modulator, AUT00063, to reduce the symptoms in people with subjective tinnitus.

Read more